IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Patent Application of

Confirmation No.: 5103

von BORSTEL et al.

Atty. Ref.: 1331-138

Appln. No. 08/460,186

T.C. / Art Unit: 1623

Filed: June 2, 1996

Examiner: Owens, H.

For: TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT

TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES

INFORMATION DISCLOSURE STATEMENT

February 25, 2005

Hon. Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Attached is a Form PTO-1449 listing the documents relied upon by Applicants in their arguments filed as a First Submission under Rule 129(a) on February 23, 2005 as well as U.S. patents disclosing compounds similar to those disclosed in this application.

This Information Disclosure Statement (IDS) is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 CFR § 1.97(f), to enable Applicants to comply fully. In particular, if any of the listed documents are missing or incomplete, please contact the undersigned who will provide another copy.

As provided by 37 CFR §§ 1.97(g) and (h), no inference should be made that this information and the listed references are prior art merely because they have been submitted for consideration. Furthermore, no representation is being made that a search 1)

von Borstel et al. - Appln. No. 08/460,186

has been conducted or that this statement encompasses all possible material information.

Consideration of the foregoing and enclosures, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per M.P.E.P. § 609, are earnestly solicited. The Examiner is invited to contact the undersigned if any further information is needed.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Gary R. Tanigawa Reg. No. 43,180

1100 North Glebe Road, 8th Floor Arlington, VA 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100

CITATION

CITATION

(Use several sheets if necessary)

APPLN. NO. ATTY. DKT. NO.

08/460,186 1331-138

APPLICANT

VON BORSTEL et al.

FILING DATE GROUP

June 2, 1995 1623

U.S. PATENT DOCUMENTS

				U.S. PATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
	AR	5,246,708	09/1993	von Borstel et al.	<u> </u>		, , , , , , , , , , , , , , , , , , ,
··	BR	5,470,838	11/1995	von Borstel et al.			
•	CR	5,583,117	12/1996	von Borstel et al.			
	DR	5,691,320	11/1997	von Borstel et al.		****	
	ER	5,736,531	04/1998	von Borstel et al.			
	FR	5,770,582	06/1998	von Borstel et al.			
	GR	5,968,914	10/1999	von Borstel et al.			
	HR	6,020,320	02/2000	von Borstel et al.			
	IR	6,020,322	02/2000	von Borstel et al.			
	JR	6,054,441	04/2000	von Borstel et al.			
	KR	6,060,459	05/2000	von Borstel et al.			
	LR	6,103,701	08/2000	von Borstel et al.			
	MR	6,232,298	05/2001	von Borstel et al.			
	NR	6,255,290	07/2001	von Borstel et al.	***************************************		
	OR	6,258,795	07/2001	von Borstel et al.			
	PR	6,274,563	08/2001	von Borstel et al.			
	QR	6,297,222	10/2001	von Borstel et al.			
	RR	6,306,834	10/2001	von Borstel et al.	· · · · · · · · · · · · · · · · · · ·		
	SR	6,316,426	11/2001	von Borstel et al.			
	TR	6,329,350	12/2001	von Borstel et al.			
	UR	6,344,447	02/2002	von Borstel et al.			
	VR	6,348,451	02/2002	von Borstel et al.			
	WR	6,403,565	06/2002	von Borstel et al.			
	XR	6,417,170	07/2002	von Borstel et al.			
	YR	6,465,440	10/2002	von Borstel et al.			
	ZR	6,472,378	10/2002	von Borstel et al.			
1	AAR	6,743,782	06/2004	von Borstel et al.			
			FC	REIGN PATENT DOCUMENTS			

DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO
BBR CCR

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

- DDR Kelsen et al. "Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer" J. Clin. Oncol. 15:1511-1517 (1997)
- EER Peters et al. "In vitro biochemical and in vivo biologicals studies of the uridine 'rescue' of 5-fluorouracil" Brit. J. Cancer 57:259-265 (1988)

 FFR

GGR *Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.